Vir Biotechnology, Inc. (($VIR)) announced an update on their ongoing clinical study. Vir Biotechnology, Inc. is conducting a Phase 1 study titled ...

A new study published in Nature Biotechnology shows that stem cell differentiation is linked to cellular structures called ...

MAIA Biotechnology, Inc. (($MAIA)) announced an update on their ongoing clinical study. MAIA Biotechnology, Inc. has announced a new Phase III ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% ...

UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...

Vir's Phase 2 trial saw 39% and 46% HBsAg loss in doublet and triplet regimens for patients with low baseline HBsAg. 100% of participants in the triplet regimen with HBsAg loss achieved anti-HBs ...

Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced a ...

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks.

On Tuesday, Sana Biotechnology Inc (NASDAQ:SANA) released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s ...